Global Celiac Disease Market - Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Celiac Disease Market - Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Celiac Disease Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 720.00 Million
Diagram Market Size (Forecast Year)
USD 1,588.86 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Celiac Disease Market, By Treatment (Infliximab, Larazotide Acetate, Gluten Free Diet, Others), Route of Administration (Oral, Parenteral), End Users (Hospitals, homecare, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)-Industry Trends and Forecast to 2029.

Celiac Disease Market

Market Analysis and Insights

Celiac disease is an autoimmune illness in which a protein called gluten damages the small intestine's membrane. Gluten can be present in grains such as rye, barley, and wheat. Gluten causes an immunological reaction that damages the villi in the small intestine (small finger-like projections in the small intestine which promote absorption). The body's ability to absorb proteins, nutrients, lipids, vitamins, carbs, and minerals is hampered by the damage. This eventually leads to malnutrition.

Data Bridge Market Research analyses that the celiac disease market was valued at USD 720 million in 2021 and is likely to reach USD 1,588.86 million by 2029 is estimated to grow at a CAGR of 10.40% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Infliximab, Larazotide Acetate, Gluten Free Diet, Others), Route of Administration (Oral, Parenteral), End Users (Hospitals, homecare, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa

Market Players Covered

Innovate Biopharmaceuticals (US), Teva Pharmaceutical Industries Ltd (Israel), ImmunogenX, LLC (US), Amgen (US), ChemoCentryx, Inc (US), Anokion SA (Switzerland), COUR Pharmaceutical (US), F. Hoffmann-La Roche Ltd (Switzerland), BioLineRx Ltd (Israel), and Takeda Pharmaceutical Company Limited (Japan)

Market Opportunities

  • The rising prevalence of celiac disease
  • Significant research and development initiatives to provide newer treatments

Market Definition

Celiac disease, also known as the celiac sprue or gluten-sensitive enteropathy. It is an immune reaction to eating gluten, a protein found in barley, wheat and rye. Eating gluten triggers an immune response in one’s small intestine.

Celiac Disease Market Dynamics

Drivers

Major factors that are expected to boost the growth of the celiac disease market in the forecast period are follows:

  • Rise in the incidence of celiac disease population

Due to the growing celiac disease population, there is a rise in the demand in the application of gluten-free products which acts as one of the major factors driving the growth of celiac disease market.

  • Increase in the investment in research and development

Robust research and development activities are bringing newer treatment options which is one of the major contributor to the market growth.

  • Growing awareness regarding the celiac disease

Rising awareness related to the disease because consumption of gluten is further anticipated to propel to the market growth.

Opportunities

In addition, the growing initiatives by the government will further provide potential opportunities for the growth of the celiac disease market in the coming years.

Restraints/Challenges

On the other hand, the decrease in the number of effective treatment is further projected to impede the growth in the celiac disease market in the timeline period. However, the increased cost involved in research might further challenge the growth of the celiac disease market in the near future.

This celiac disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on celiac disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The celiac disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Celiac Disease Market

The pandemic of COVID-19 has had a huge impact on the celiac disease market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. On the other hand, the development of vaccines and renunciation of lockdown has helped the market to advance its growth. Also the market players are investing to improve celiac disease market growth in the forecast period.

Global Celiac Disease Market

The celiac disease market is segmented on the basis of treatment, type, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Infliximab
  • Larazotide Acetate
  • Gluten Free Diet
  • Others

On the basis of treatment, the celiac disease market is segmented into infliximab, larazotide acetate, gluten free diet, others.

Route of Administration

  • Oral
  • Parenteral

On the basis of route of administration, the celiac disease market is segmented into Oral, Parenteral.

End Users

  • Hospitals
  • homecare
  • Others

On the basis of end users, the celiac disease market is segmented into hospitals, homecare, others.

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

On the basis of distribution channel, the celiac disease market is segmented into hospital pharmacy, online pharmacy, retail pharmacy.

Celiac Disease Market Regional Analysis/Insights

The celiac disease market is analysed and market size insights and trends are provided by country, treatment, type, route of administration, end users and distribution channel as referenced above.

The countries covered in the celiac disease market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America dominates the celiac disease market due to the rise in the refined healthcare expenses. Furthermore, the increase in the patient awareness level growing incidence of celiac diseases will further boost the growth of the celiac disease market in the region during the forecast period.

Europe is projected to observe significant amount of growth in the celiac disease market due to the occurrence of global market players. Moreover, the rising government support for vaccine development is further anticipated to propel the growth of the celiac disease market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Celiac Disease Market Share Analysis

The celiac disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to celiac disease market.

Some of the major players operating in the celiac disease market are:

  • Innovate Biopharmaceuticals (US)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • ImmunogenX, LLC (US)
  • Amgen (US)
  • ChemoCentryx, Inc (US)
  • Anokion SA (Switzerland)
  • COUR Pharmaceutical (US)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • BioLineRx Ltd (Israel)
  • Takeda Pharmaceutical Company Limited (Japan)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Celiac Disease Market size will be worth USD 1,588.86 million by 2029.
The Celiac Disease Market growth rate is 10.40% by 2029.
Rise in the incidence of celiac disease population and Increase in the investment in research and development are the growth drivers of the Celiac Disease Market.
The treatment, type, route of administration, end users and distribution channel are the factors on which the Celiac Disease Market research is based.
The major companies in the Celiac Disease Market are Innovate Biopharmaceuticals (US), Teva Pharmaceutical Industries Ltd (Israel), ImmunogenX, LLC (US), Amgen (US), ChemoCentryx, Inc (US), Anokion SA (Switzerland), COUR Pharmaceutical (US), F. Hoffmann-La Roche Ltd (Switzerland), BioLineRx Ltd (Israel), and Takeda Pharmaceutical Company Limited (Japan).